Archive · 13 Sep 2026
Indian Equities Face Re-Rating Hopes as Mid-Caps Look Expensive
Omniscience Capital thinks Indian stocks could do better when company profits improve later in FY27.
This improvement is expected between October 2026 and March 2027.
However, many mid-sized and small-sized companies already have expensive share prices.
Their prices suggest investors expect strong profits for several years.
That means some investors may want to check whether their portfolios are too concentrated in these stocks.
The firm does not say investors must sell all mid- and small-cap shares.
Instead, it recommends choosing companies with strong growth prospects and reasonable prices.
It sees possible opportunities in financial services, infrastructure, power and business services.
High US interest rates and rising oil prices could still hurt stock valuations.
Omniscience Capital expects Indian equities to re-rate as FY27 earnings improve in the second half.
The Nifty Smallcap 250 and Midcap 150 trade at trailing P/E multiples of about 34x and 30x, versus 20x for the Nifty 100.
The firm says elevated valuations make stock selection, earnings visibility and portfolio allocation increasingly important.
Omniscience favors banking and financial services, infrastructure and power, and business services.
Key risks include high US Treasury yields, the Federal Reserve’s September 16 decision and a recent 20%-30% rise in crude prices.
- Who
- Omniscience Capital, led in the cited comments by President and Chief Portfolio Manager Ashwin K. Shami, and investors in Indian equities.
- What
- The firm assessed elevated mid- and small-cap valuations, possible equity re-rating, portfolio rebalancing and investment opportunities.
- When
- The expected earnings improvement is in H2 FY27, from October 2026 to March 2027; the US Federal Reserve’s September 16 policy decision is described as a near-term trigger.
- Where
- Indian equity markets, with global influences including US Treasury yields and Middle East tensions.
- Why
- Corporate earnings and domestic institutional capital could support equities, but expensive valuations, high bond yields and rising crude prices create risks.
Rebalance and Select Carefully
Stay Invested for Potential Re-Rating
Mid- and small-cap exposure
Rebalance and Select Carefully
Investors should review portfolios for excessive concentration in expensive mid- and small-cap stocks because future earnings growth may already be priced in and de-rating risk is significant.
Stay Invested for Potential Re-Rating
Investors do not necessarily need to exit these segments; selective holdings with strong earnings visibility may still benefit if corporate earnings accelerate.
Response to market consolidation
Rebalance and Select Carefully
Consolidation is a reason to reassess valuations, allocation and whether underlying businesses can justify their prices.
Stay Invested for Potential Re-Rating
Omniscience Capital describes consolidation as an accumulation window rather than a reason for anxiety or speculative selling, favoring high-quality growth businesses available at discounted valuations.
Investment opportunity
Rebalance and Select Carefully
High valuations in some market segments mean investors should avoid chasing recent performance and focus on reasonably valued businesses.
Stay Invested for Potential Re-Rating
A re-rating could be supported by improving FY27 earnings, domestic institutional buying, foreign investor interest and approximately 7% real GDP growth.
- Expected earnings period
- H2 FY27, covering October 2026 to March 2027
- Small-cap valuation
- Nifty Smallcap 250 trailing P/E of around 34x
- Mid-cap valuation
- Nifty Midcap 150 trailing P/E of around 30x
- Large-cap comparison
- Nifty 100 trailing P/E of around 20x
- GDP outlook
- FY27 real GDP growth estimated at around 7%
- Preferred sectors
- Banking and financial services, infrastructure and power, and business services
- Market risks
- US 10-year Treasury yields near 4.6%-4.7% and crude oil up 20%-30% over the last month